Deng Yuqi, Pan Liqin, Xu Yifan, Duan Yifei, Chen Erhao, Luo Yumei, Feng Huijuan, Ouyang Wei
Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, 510220, China.
J Endocrinol Invest. 2025 Apr;48(4):905-918. doi: 10.1007/s40618-024-02507-y. Epub 2024 Dec 9.
To investigate the pathological characteristics of aggressive variants of papillary thyroid carcinoma (PTC) and evaluate the efficacy of radioiodine (RAI) therapy for these variants.
We analysed 129 patients with aggressive variants of PTC and compared them to those of 4460 patients with non-aggressive variants. And we examined the efficacy of RAI therapy in 70 eligible patients with aggressive variants of PTC and 2530 eligible patients with non-aggressive variants of PTC.
Aggressive and non-aggressive variants of PTC demonstrated a greater degree of variability in terms of age, multifocality, capsular invasion, vascular invasion, extrathyroidal invasion, lymph node metastases, disease stage, risk stratification, N stage, comorbid with Hashimoto thyroiditis (HT) and comorbid with nodular goiter (NG). Propensity score matching method showed poor efficacy of RAI treatment in patients with aggressive variants of PTC compared with non-aggressive variants. Multifactorial analysis showed that comorbid NG was an independent risk factor for poor effectiveness of RAI treatment for aggressive PTC variants ((hazard ratio (HR) 3.027; 95% confidence interval (CI), 1.295-7.075).
Aggressive variants of PTC demonstrated a higher degree of aggressiveness and poor efficacy of RAI therapy compared to non-aggressive variants, especially comorbid with NG, which may require higher therapeutic 131I dosage.
研究甲状腺乳头状癌(PTC)侵袭性变体的病理特征,并评估放射性碘(RAI)治疗这些变体的疗效。
我们分析了129例PTC侵袭性变体患者,并将他们与4460例非侵袭性变体患者进行比较。我们还检查了70例符合条件的PTC侵袭性变体患者和2530例符合条件的PTC非侵袭性变体患者的RAI治疗疗效。
PTC的侵袭性和非侵袭性变体在年龄、多灶性、包膜侵犯、血管侵犯、甲状腺外侵犯、淋巴结转移、疾病分期、风险分层、N分期、合并桥本甲状腺炎(HT)和合并结节性甲状腺肿(NG)方面表现出更大程度的变异性。倾向评分匹配法显示,与非侵袭性变体相比,RAI治疗在PTC侵袭性变体患者中的疗效较差。多因素分析表明,合并NG是RAI治疗侵袭性PTC变体疗效不佳的独立危险因素(风险比(HR)3.027;95%置信区间(CI),1.295 - 7.075)。
与非侵袭性变体相比,PTC侵袭性变体表现出更高的侵袭性和RAI治疗疗效较差,尤其是合并NG时,可能需要更高剂量的治疗性131I。